When was Medite founded?

Medite was founded in 1978 and raised its 1st funding round 26 years after it was founded.

Where is Medite located?

Medite is headquartered in Orlando, United States.

How many employees does Medite have?

As of May 31, 2026, the latest employee count at Medite is 13.

Is Medite a funded company?

Medite is a funded company, having raised a total of $2.57M across 14 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Jul 2004.

When was the latest funding round of Medite?

Medite's latest funding was a $***** Post IPO round on Oct 11, 2018, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.46B in funding in 2026 to date.

What is the annual revenue of Medite?

Annual revenue of Medite is between $5M and $25M as on Oct 25, 2018

Where does Medite rank among its competitors?

Medite ranks 95th amongst 445 active competitors, of which 127 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of Medite?

Medite's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

Medite - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Medite provides diagnostic solutions for cancer diagnostics. They are developing products for Histology and Cytology including Microtome, Multistainer, Coverslipper, Electronic Engraving Pen, Tissue Drying Oven, Paraffin Recycling Device and Ultrasonic Decalcifying Automat.

Website: medite-group.com
Social
Email ID: *****@medite-group.com
Phone Number: +1 **********

Key Metrics

Founded Year

1978

Location

Orlando, United States

Stage

Public

Total Funding

$2.57M in 14 rounds

Latest Funding Round

Post IPO, Oct 11, 2018, $*****

Investors

Visionary Private Equity Group & 1 more

Ranked

95^th among 445 active competitors

Annual Revenue

$5M - $25M as on Oct 25, 2018

Employee Count

13 as on May 31, 2026

Similar Companies

Guardant Health & 570 more

Exit Details

Public

View Medite's full profile

Medite is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MEDITE CANCER DIAGNOSTICS, INC. CIN: 75439 , United States, Active	Dec 14, 1998	$5M - $25M (As on Oct 25, 2018)	71 (As on Dec 31, 2017)	-

Medite got listed on Mar 08, 1995.

Click here to take a look at Medite's IPO in detail

Medite has raised a total funding of $2.57M over 14 rounds. Its first funding round was on Jul 2004. Medite has 2 institutional investors.

Here is the list of recent funding rounds of Medite:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2018	8069727	Post IPO	7820079	6067581	9790687	5338458
Jun 28, 2018	6223897	Post IPO	5532776	9544513	8054735	8097629
Feb 22, 2018	8857716	Post IPO	5793176	7669908	9607982	4490374

Access funding benchmarks and valuations. Sign up today!

View details of Medite's funding rounds and investors

Medite's employee count trend

Medite has 13 employees as of May 26. Here is Medite's employee count trend over the years:

Uncover Medite's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Medite include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Medite, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Khosla Ventures, Orbimed & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Casdin Capital & 11 others	71/100
5th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Merck Global Health Innovation Fund, DFJ Growth ... & 19 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
95th	Medite 1978, Orlando (United States), Public	Developer of products for histology and cytology	$2.57M	Visionary Private Equity Group, GPB Capital	41/100